newsfilter
← Latest News
Business Wire·

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

BIAFBIAFW
  • bioAffinity Technologies announced new data on sputum-based tests for measuring cellular & soluble inflammatory protein biomarkers at CHEST 2026.
  • The investigational test utilizes a proprietary flow cytometry & AI platform to characterize lung inflammation in asthma & COPD.
  • Research demonstrates the ability to detect specific biologic drug targets including TSLP, CRLF2, IL4-Ra (CD124), & IL-5.
  • Data indicates the test can analyze immune cell populations & inflammatory proteins to support precision medicine approaches for patient selection & monitoring.
  • The global asthma therapeutics market is projected to reach $47.6 billion by 2034, up from an estimated $29.7 billion in 2025.
  • Dr. Gordon Downie will present on the clinical use of CyPath Lung & sputum-based testing in a session on October 21, 2026.
  • A poster titled "Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma" will be presented on October 20, 2026, at the Phoenix Convention Center.
  • The study analyzed sputum samples from asthma patients, COPD patients, smokers, & healthy individuals using flow cytometry, ELISA, & machine learning.
  • CyPath Lung is a commercially available noninvasive test for early lung cancer detection with 92% sensitivity & 87% specificity in high-risk patients.
  • The sputum-based test described is investigational & not yet approved for clinical or diagnostic use.